|1.Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, Hu HM, Hsu PI, Wang JY, Wu DC*. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2018 Sep 1.
2.Chen CF, Lin YC, Tsai HL, Huang CW, Yeh YS, Ma CJ, Lu CY, Hu HM, Shih HY, Shih YL, Sun LC, Chiu HC, Wang JY. Short- and long-term outcomes of laparoscopic-assisted surgery, mini-laparotomy and conventional laparotomy in patients with Stage I-III colorectal cancer. J Minim Access Surg. 2018 Oct-Dec;14(4):321-334.
3.Hsu WH, Wang YK, Hsieh MS, Kuo FC, Wu MC, Shih HY, Wu IC, Yu FJ, Hu HM, Su YC, Wu DC*. Insights into the management of gastric antral vascular ectasia (watermelon stomach). Therap Adv Gastroenterol. 2018 Jan 14;11:
4.Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC*. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017 Sep;112(9):1374-1381.
5.Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC*. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis. 2017 Sep;18(9):537-542.
6.Ma CJ, Huang CW, Yeh YS, Tsai HL, Hu HM, Wu IC, Cheng TL, Wang JY*. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Oncol Res. 2017 May 24;25(5):673-679.
7.Cheng CY, Wu IC, Chen YT, Hu HM*. A rare hepatoid adenocarcinoma from the gastric remnant. Kaohsiung J Med Sci. 2016 Sep;32(9):482-3.
8.Kuo CH, Liu CJ, Yang CC, Kuo FC, Hu HM, Shih HY, Wu MC, Chen YH, Wang HM, Ren JL, Wu DC, Chang LL. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. Medicine (Baltimore). 2016 May;95(21):e3458.
9.Huang CW, Yeh YS, Su WC, Tsai HL, Choy TK, Huang MY, Huang CM, Wu IC, Hu HM, Hsu WH, Su YC, Wang JY. Robotic surgery with high dissection and low ligation technique for consecutive patients with rectal cancer following preoperative concurrent chemoradiotherapy. Int J Colorectal Dis. 2016 Jun;31(6):1169-77
10.Hsu WH, Wu IC, Hu HM*. Bleeding from jejunal diverticulum located by angiography and treated by enteroscopy. Gastrointest Endosc. 2016 Apr;83(4):838-9
11.Jheng GH, Wu IC, Shih HY, Wu MC, Kuo FC, Hu HM, Liu CJ, Hsu WH, Hu CT, Bair MJ, Kuo CH, Wu DC, Hsu PI*. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. Biomed Res Int. 2015;2015:163960.
12.Hsu WH, Lu CY, Hu HM. Sigmoid colon cancer with intussusception reduced by colonoscopy. Gastrointest Endosc. 2015 Oct;82(4):753.
13.Hsu WH, Kuo FC, Hu HM, Hsu PI, Wu DC, Kuo CH*. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis. Kaohsiung J Med Sci. 2015 May;31(5):255-9.
14.Keenan CM, Storr MA, Thakur GA, Wood JT, Wager-Miller J, Straiker A, Eno MR, Nikas SP, Bashashati M, Hu H, Mackie K, Makriyannis A, Sharkey KA*. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol. 2015 May;172(9):2406-
15.Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC*. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014 Nov 21;20(43):16029-36.
16.Kuo FC, Wu CY, Kuo CH, Wu CF, Lu CY, Chen YH, Chen CY, Lo YC, Wu MT, Hu HM*. The utilization of a new immunochromatographic test in detection of Helicobacter pylori antibody from maternal and umbilical cord serum. Biomed Res Int. 2014;2014:568410.
17.Hsu WH, Kuo CH, Wang SS, Lu CY, Liu CJ, Chuah SK, Kuo FC, Chen YH, Huang YB, Hou MF, Wu DC, Hu HM*. Acid suppressive agents and risk of Mycobacterium Tuberculosis: case-control study. BMC Gastroenterol. 2014 May 13;14:91
18.Liu CJ, Kuo FC, Hu HM, Chen CY, Huang YB, Cheng KH, Yokoyama KK, Wu DC, Hsieh S, Kuo CH*. 17β-Estradiol inhibition of IL-6-Src and Cas and paxillin pathway suppresses human mesenchymal stem cells-mediated gastric cancer cell motility. Transl Res. 2014 Sep;164(3):232-43.
19.Wu TS, Hu HM, Kuo FC, Kuo CH*. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014 Apr;30(4):167-72.
20.Yeh YS, Huang ML, Chang SF, Chen CF, Hu HM, Wang JY*. FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. Med Princ Pract. 2014;23(5):478-81.
21.Hsu WH, Kuo CH, Wu IC, Lu CY, Wu DC, Hu HM*. Superficial esophageal squamous cell carcinoma over esophageal varices treated by endoscopic submucosal dissection. Gastrointest Endosc. 2014 May;79(5):833-4. doi:
22.Lu CY, Huang CW, Hu HM, Tsai HL, Huang CM, Yu FJ, Huang MY, Chang SF, Huang ML, Wang JY. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Transl Res. 2014 Aug;164(2):169-76.
23.Kuo CH, Liu CJ, Lu CY, Hu HM, Kuo FC, Liou YS, Yang YC, Hsieh MC, Lee OK, Wu DC, Wang SS*, Chen YL*. 17β-Estradiol Inhibits Mesenchymal Stem Cells-Induced Human AGS Gastric Cancer Cell Mobility via Suppression of CCL5-Src/Cas/Paxillin Signaling Pathway. Int J Med Sci 2014; 11(1);7-16
24.Kuo CH, Wang SS, Lu CY, Hu HM, Kuo FC, Weng BC, Wu CC, Liu CJ, Tsai PY, Lee TC, Chen LW, Cheng KH, Chang LL, Wu DC*. Long-Term Use of Probiotic-Containing Yogurts Is a Safe Way to Prevent Helicobacter pylori: Based on a Mongolian Gerbil's Model. Biochem Res Int. 2013;2013:594561.
25.Chang YP, Chiu GF, Kuo FC, Lai CL, Yang YH, Hu HM, Chang PY, Chen CY, Wu DC, Yu FJ*. Eradication of Helicobacter pylori Is Associated with the Progression of Dementia: A Population-Based Study. Gastroenterol Res Pract. 2013;2013: 175729
26.Ou CH, Kuo FC, Hsu WH, Lu CY, Yu FJ, Kuo CH, Wang JY, Wu MT, Shiea J, Wu DC, *Hu HM. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. J Dig Dis. 2013 Sep;14(9):474-83.
27.Lin CC, Shih HY, Kuo CH, Hu HM, Chen YW, Wu DC, Su YC. Nodular lymphoid hyperplasia in endoscopic and FDG-PET/CT ((18)F-fluoro-2-deoxyglucose positron emission tomography/computerized tomography) imaging. Kaohsiung J Med Sci. 2013 Jul;29(7):396-9.
28.Chen YY, Hsu WH, Hu HM, Wu DC, Lin WY. A case of alpha-fetoprotein-producing esophageal adenocarcinoma. Kaohsiung J Med Sci. 2013 Feb;29(2):106-10.
29.Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. J Antimicrob Chemother. 2013 Jan;68(1):222-8.
30. Hu H, Ho W, Mackie K, Pittman QJ, Sharkey KA*. Brain CB(1) receptor expression following lipopolysaccharide-induced inflammation. Neuroscience.2012 Dec 27;227:211-22
31.Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract. 2012;2012:168361.
32.Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis. 2011 Aug;17(8):1651-64.
33.Hsu WH, Wang SS, Kuo CH, Chen CY, Chang CW, Hu HM, Wang JY, Yang YC, Lin YC, Wang WM, Wu DC, Wu MT, Kuo FC. Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World J Gastroenterol. 2010 Jun 21;16(23):2926-30.
34.Kuo CH, Hu HM, Tsai PY, Wu IC, Yang SF, Chang LL, Wang JY, Jan CM, Wang WM, Wu DC. Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World J Gastroenterol. 2009 Oct 21;15(39):4907-14
35.Hu HM, Kuo CH, Lee CH, Wu IC, Lee KW, Lee JM, Goan YG, Chou SH, Kao EL, Wu MT, Wu DC. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol. 2009 May 23;9:37.
36.Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother. 2009 May;63(5):1017-24.
37.Kuo CH, Hu HM, Tsai PY, Yang SF, Chang LL, Wang JY, Chen A, Jan CM, Wang WM, Wu DC. A better method for confirming Helicobacter pylori infection in Mongolian gerbils. J Gastroenterol. 2008;43(1):32-7.
38.Kuo CH, Hu HM, Tsai PY, Liu CJ, Yu FJ, Chang K, Pan YS, Chen A, Jan CM, Wang WM, Wu DC. A better method for preventing infection of percutaneous endoscopic gastrostomy. J Gastrointest Surg. 2008 Feb;12(2):358-63.
39.Hu HM, Kuo CH, Lo YC, Wu MT, Wu IC, Lu CY, Su YC, Yu FJ, Lee YC, Lin SR, Liu CS, Jan CM, Wang WM, Wu DC. Evaluation of the two immunochromatographic methods for detecting urine and serum IgG antibodies to Helicobacter pylori and comparison of accuracy and clinical utility. Hepatogastroenterology. 2007 Jan-Feb;54(73):119-23.
40.Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, Hsieh JS, Chong IW, Cheng TL, Lin SR. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep. 2006 Dec;16(6):1245-52.